Welcome to our dedicated page for Vivani Medical SEC filings (Ticker: VANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vivani Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vivani Medical's regulatory disclosures and financial reporting.
Vivani Medical, Inc. outlines its strategy as a clinical-stage biopharma company developing miniature, ultra long-acting GLP-1 drug implants using its NanoPortal™ technology to address chronic diseases where medication adherence and tolerability are major challenges.
The company’s lead programs include NPM-139 and NPM-133 semaglutide implants for chronic weight management and type 2 diabetes, and NPM-115 and OKV-119 exenatide-based implants for humans and companion animals. Vivani reports positive preclinical weight-loss and liver-fat data and successful first-in-human results from the LIBERATE-1 trial supporting its platform.
Vivani also describes strategic efforts to separate its neurostimulation business into Cortigent, which may proceed via a spin-off or IPO, and expands its animal-health collaboration with Okava. The filing details robust intellectual property coverage, manufacturing capabilities in California, and the U.S. regulatory framework expected to govern future approvals.
Vivani Medical director and 10% owner Gregg Williams reported significant open-market purchases of Vivani Medical, Inc. common stock. On two private sale transactions dated in Share Purchase Agreements on May 12, 2025 and August 11, 2025, he purchased 1,310,680 shares at $1.03 per share and 264,551 shares at $1.26 per share, respectively. The related footnotes state gross proceeds of $1,350,000.40 for the first transaction and $333,334.26 for the second. After these transactions, he directly and indirectly controls 36,156,383 shares, including 4,799,200 shares held directly and additional shares held through the Gregg G. Williams 2006 Trust, Williams International Co. LLC, Sam Williams Family Investments LLC, and the Sam B. Williams 1995 Generation-Skipping Trust, over which he has voting and dispositive power.
Williams Gregg reported open-market purchase transactions in a Form 4 filing for VANI. The filing lists transactions totaling 1,866,492 shares at a weighted average price of $1.06 per share. Following the reported transactions, holdings were 29,781,952 shares.
Vivani Medical director and 10% owner Gregg Williams reported buying 1,351,351 shares of Vivani common stock in a private sale on January 27, 2026. The purchase price was $1.48 per share, matching the last reported Nasdaq sale price on January 23, 2026, for gross proceeds of $1,999,999.48.
After this transaction, Williams beneficially owns 32,714,660 shares directly and through related entities. These include 4,799,200 shares in his own name, 25,789,708 shares held by the Gregg G. Williams 2006 Trust, and additional holdings through several Williams family investment entities over which he has voting and dispositive power.
Vivani Medical, Inc. entered into two equity transactions on January 25, 2026. The company agreed to sell 1,351,351 common shares in a private placement to an entity affiliated with its board chairman at $1.48 per share, generating gross proceeds of about $2.0 million with no warrants, discounts, or placement fees. At the same time, Vivani arranged a registered direct offering of 1,689,200 common shares expected to raise roughly $2.5 million in gross proceeds under its existing shelf registration, paying a 7% cash fee to the placement agent plus up to $125,000 of expenses. Directors and officers agreed to a 60-day lock-up after the registered offering closes, limiting insider share sales during that period.
Vivani Medical, Inc. is conducting a registered direct offering of 1,689,200 shares of common stock at $1.48 per share, raising approximately $2.0 million in net proceeds. At the same time, an entity affiliated with director Gregg Williams has agreed to buy 1,351,351 additional shares in a concurrent private placement, expected to add about $1.9 million, for combined net proceeds of roughly $3.9 million. Vivani plans to use these funds, together with existing cash, to support research and clinical development of its long-acting drug implant programs, as well as working capital and general corporate purposes, and currently expects its cash resources to fund operations into mid 2027. Following the offering and the concurrent private placement, Vivani expects to have 81,206,080 shares of common stock outstanding, and notes that new buyers will experience dilution compared with earlier shareholders.
Vivani Medical, Inc. director and 10% owner Gregg Williams reported additional insider purchases of the company’s common stock. On January 15, 2026, he reported the purchase of 1,473,214 shares at $1.12 per share under a private sale tied to a March 26, 2025 share purchase agreement, with gross proceeds of $1,649,999.68. He also reported purchasing 264,551 shares at $1.26 per share through a separate private sale under an August 11, 2025 share purchase agreement, with gross proceeds of $333,334.26.
After these transactions, Williams is reported as beneficially owning a total of 31,363,309 shares of Vivani Medical common stock. This includes 4,799,200 shares held directly and additional shares held through the Gregg G. Williams 2006 Trust, Williams International Co. LLC, Sam Williams Family Investments LLC, and the Sam B. Williams 1995 Generation-Skipping Trust, over which he has voting and dispositive power.
Vivani Medical, Inc. disclosed that a director and 10% owner purchased common stock in two private sale transactions. One transaction covered 1,473,214 shares at $1.12 per share under a Share Purchase Agreement dated as of March 26, 2025, with gross proceeds of $1,649,999.68. A second transaction covered 264,551 shares at $1.26 per share under a Share Purchase Agreement dated as of August 11, 2025, with gross proceeds of $333,334.26, in each case priced at the last reported Nasdaq sale price on the day before the agreement date.
Following these purchases, the reporting person beneficially owns 29,625,544 shares of Vivani common stock held directly and through several trusts and investment entities, and Gregg Williams has voting and dispositive power over all of these shares.
Vivani Medical, Inc. insider activity: A reporting person who is both a director and 10% owner of VANI disclosed two private purchases of Vivani Medical common stock dated 11/15/2025. One transaction involved buying 1,473,214 shares at $1.12 per share under a Share Purchase Agreement dated March 26, 2025, with gross proceeds of $1,649,999.68. A second transaction involved buying 264,550 shares at $1.26 per share under a Share Purchase Agreement dated August 11, 2025, with gross proceeds of $333,333.00. After these transactions, the reporting person is shown as beneficially owning 27,887,779 shares of Vivani common stock through a combination of direct holdings, family trusts, and related entities over which Gregg Williams has voting and dispositive power.
Vivani Medical (VANI) filed its Q3 2025 10-Q, reporting continued operating investment as it advances subdermal GLP-1 implant programs. Cash and cash equivalents were $2.6 million at September 30, 2025, down from $18.4 million at year-end, with total assets of $25.0 million and stockholders’ equity of $1.3 million. Net loss was $6.5 million for the quarter and $20.0 million year-to-date, driven by R&D and G&A expenses.
The company highlighted clinical and portfolio progress: LIBERATE-1, the first-in-human study of its NanoPortal technology, met primary objectives with a positive safety and tolerability profile, informing plans to prioritize NPM-139 (semaglutide implant). Vivani outlined plans to initiate a Phase 1 study for NPM-139 in the first half of 2026, pending regulatory clearance. To support operations, Vivani entered equity purchase agreements expected to bring $18.6 million between September 30, 2025 and July 15, 2026, and subsequently raised approximately $6.0 million in a private placement and $9.7 million gross in a registered direct offering in October. Shares outstanding were 72,952,235 as of November 12, 2025.